Liprolog Junior Kwikpen

Insulin lispro, the active ingredient in Liprolog Junior Kwikpen, is a rapid‑acting insulin analog presented as a prefilled KwikPen for subcutaneous use. It is used to control blood glucose in people with diabetes mellitus, both type 1 and type 2, and is administered by injection. GNH USA supplies Liprolog Junior Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog Junior Kwikpen contains insulin lispro, a rapid‑acting insulin analog that works within the insulin‑dependent glucose regulation pathway. It is indicated for the following clinical situations: - Type 1 diabetes mellitus: provides mealtime glucose control and reduces post‑prandial hyperglycaemia. - Type 2 diabetes mellitus: used when oral agents are insufficient to achieve glycaemic targets. - Intensive insulin therapy (basal‑bolus regimen): serves as the rapid‑acting component to complement basal insulin for tight glucose management.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glucose utilisation. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment requiring immediate assistance. - Anaphylactic reaction: systemic allergic response that may include rash, bronchospasm, or hypotension. - Hypokalemia: low serum potassium levels, particularly with high insulin doses. - Diabetic ketoacidosis: possible if insulin therapy is abruptly discontinued.

When using Liprolog Junior Kwikpen, consider the following precautions: - Dose adjustment: tailor insulin dose to carbohydrate intake, physical activity, and glucose monitoring results. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose promptly. - Renal impairment: monitor renal function and adjust dose as needed because insulin clearance may be reduced. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Insulin lispro may interact with several medicines that affect glucose levels or insulin action. Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms, making detection difficult. - Alcohol: potentiates insulin’s glucose‑lowering effect and increases hypoglycaemia risk. - Concurrent insulin products: additive glucose‑lowering effect may cause severe hypoglycaemia. Moderate Interactions (Monitor Closely): - Glucocorticoids: raise blood glucose and may require higher insulin doses. - Thiazide diuretics: can increase blood glucose modestly. - ACE inhibitors and ARBs: may enhance insulin sensitivity, necessitating dose review.